Patents

@patent{特許第7199054号(P7199054),

title = {サンプル中の元素の質量分析方法、該質量分析方法に用いる分析用デバイス、および、サンプル捕捉用キット},

author = {安井, 隆雄 and 馬場, 嘉信 and 青木, 元秀 and 梅村, 知也},

year  = {2022},

date = {2022-12-22},

urldate = {2022-12-22},

booktitle = {特許公報(B2)},

number = {特許第7199054号(P7199054)},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}

@patent{Aoki2014,

title = {金属元素の捕集方法及び金属元素の除去方法},

author = {青木,元秀 and 都筑,幹夫 and 松井,雄一郎 and 藤原,祺多夫},

year  = {2014},

date = {2014-10-23},

number = {特開2014-198325(P2014-198325A)},

location = {公開特許公報(A)},

abstract = {【課題】重金属類又は有価金属類又は有害金属類を含有する廃水、廃土あるいは汚泥から、環境にやさしく、安価で、安定に、かつ、効率のよく重金属又は有価金属又は有害金属を捕集して、重金属類、有価金属類又は有害金属類を除去する処理方法を提供すること。},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}

@patent{Arikuni2007,

title = {Transthyretin, apolipoprotein AI and related factors as markers for evaluating the effectiveness of interferon therapy against hepatitis C.},

author = {Takashi Arikuni and Toshikazu Yoshikawa and Toshiya Oki and Motohide Aoki and Eri Kikawa and Tsuguhisa Yamaguchi and Shoichi Mafune and Yutaka. Takahashi},

year  = {2007},

date = {2007-10-01},

booktitle = {Jpn. Kokai Tokkyo Koho},

number = {JP2007278811A},

pages = {99pp.},

publisher = {Biomarker Science Co., Ltd., Japan .},

abstract = {The invention provides markers and methods for evaluating effectiveness of interferon therapy against hepatitis C. The markers are transthyretin or deriv., apolipoprotein AI or deriv., their genetic products, and those factors (e.g. nucleic acid, polypeptide, lipid, carbohydrate, low org. mol., complex mol. or antibody) that specifically interact with them. The methods and devices include mass analyzer, NMR, X-ray analyzer, SPR, chromatog., immunoassay, biochem., electrophoresis, isotope label, tandem affinity purifn., phys. mean, laser microdissection or combination of them. The invention uses ion exchanger or metal chelate to capture marker mol. in biol. sample (e.g. body fluid, blood) and perform anal. with the above anal. device. [on SciFinder(R)]},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}

@patent{Arikuni2007a,

title = {Disease diagnostic method, substance evaluation method, substance screening method, and disease preventive agent.},

author = {Takashi Arikuni and Toshiya Oki and Motohide Aoki and Eri Kikawa and Yuji Naito and Toshikazu. Yoshikawa},

year  = {2007},

date = {2007-03-01},

booktitle = {Jpn. Kokai Tokkyo Koho},

number = {JP2007064747A},

pages = {20pp.},

publisher = {Biomarker Science Co., Ltd., Japan .},

abstract = {A disease diagnostic method is provided, which enables to evaluate the presence/absence of development of a disease accompanying the increase in blood cholesterol level and/or blood neutral lipid level, or its future development risk. The disease diagnostic method comprises comparing the concn. of at least one of three marker substances in body fluid (e.g., blood) of a test subject with the ref. value. The marker substances used in this method are the proteins which are bound with a weak cation exchanger at pH7.0 or 4.0, and generate the ion peak with the particular mass/charge ratio (ca. 3060, ca. 8330, ca 8980) by mass spectrometry. The concn. of the marker substance in body fluid can also be measured by trapping it to a carrier on which a substance possessing the affinity to the marker substance is immobilized. Also provided is a substance evaluation method, with which a test substance is evaluated by using the marker substances as an index concerning its improvement effect on a disease accompanying the increase in blood cholesterol level and/or blood neutral lipid level, or its redn. effect on the disease future development risk. Also provided are a substance screening method using this substance evaluation method, and a disease preventive agent contg. acetic acid as an effective component. [on SciFinder(R)]},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}

@patent{Arikuni2006,

title = {Method of assessing effectiveness of interferon therapy and kit for assessing the same.},

author = {Hisashi Arikuni and Toshikazu Yoshikawa and Toshichika Ooki and Motohide Aoki and Eri Kigawa and Tsugihisa Yamaguchi and Syouichi Mafune and Yutaka. Takahashi},

year  = {2006},

date = {2006-10-01},

booktitle = {PCT Int. Appl.},

number = {WO2006107078A1},

pages = {134pp.},

publisher = {Biomarker Science Co., Ltd., Japan .},

abstract = {The effectiveness of interferon therapy is assessed in advance. By using the concn. of a marker substance in the body fluid of a patient as an indicator, it is assessed whether or not interferon therapy is effective for the patient. A method of measuring the concn. of a marker substance can be carried out by entrapping the marker substance in a carrier such as a substrate having an ion exchanger or a metal chelator immobilized thereon and performing mass spectrometry. With the use of a kit for assessing the effectiveness of interferon therapy comprising a carrier having a substance with affinity for the marker substance immobilized thereon, it can be more simply and promptly assessed whether or not the interferon therapy is effective. [on SciFinder(R)]},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}

@patent{Arikuni2006a,

title = {Inflammatory bowel disease diagnostic method/kit using protein chip and mass spectrometry.},

author = {Hisao Arikuni and Yuji Naito and Motohide Aoki and Toshiya Oki and Tsuguhisa Yamaguchi and Shoichi Mafune and Yutaka Takahashi and Toshikazu. Yoshikawa},

year  = {2006},

date = {2006-09-01},

booktitle = {Jpn. Kokai Tokkyo Koho},

number = {JP2006258629A},

pages = {25pp.},

publisher = {Biomarker Science Co., Ltd., Japan .},

abstract = {A diagnostic method for inflammatory bowel disease such as ulcerative colitis is provided, which utilizes body fluid as a test sample, and is applicable to a multimarker system. The method comprises comparing the concn. of a marker substance in body fluid (e.g., blood) with a normal value, and thereby, diagnosing inflammatory bowel disease. In this method, at least one kind of protein among 15 kind of proteins is used as a marker substance. The concn. of the marker substance can be measured by mass spectrometry. The marker substance can be trapped with a carrier on which a substance (e.g., ion exchanger, metal chelate body) possessing the affinity to the marker substance is immobilized, and then, the concn. of the marker substance can also be measured. It is feasible to perform diagnosis of inflammatory bowel disease using an inflammatory bowel disease diagnostic kit contg. the carrier on which the substance possessing the affinity to the marker substance is immobilized,. Diagrams describing the diagnostic method flow are given. [on SciFinder(R)]},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}

@patent{Yoshikawa2006,

title = {Method and kit for predicting or diagnosing diabetes by multi-marker system using immunoassay.},

author = {Toshikazu Yoshikawa and Yuji Naito and Hisashi Arikuni and Satomi Akagiri and Kenichi Mihara and Toshichika Ooki and Tsugihisa Yamaguchi and Syouichi Mafune and Yutaka Takahashi and Yumiko Nakashima and Motohide Aoki and Mari Kobayashi and Eri. Kigawa},

year  = {2006},

date = {2006-07-01},

booktitle = {PCT Int. Appl.},

number = {WO2006073195A1},

pages = {184 pp.},

publisher = {Biomarker Science Co., Ltd, Japan .},

abstract = {A method/kit for diagnosing or pre-diagnosing diabetes is provided, which is useful for detecting or preventing diabetes, and applicable to a multi-marker system. The method comprises selecting one or more proteins selected from the group consisting of transthyretin, apolipoprotein CII, apolipoprotein CIII, serum albumin, and substances related to them in blood, comparing the concn. of each substance with a normal value, and thereby, performing diabetes diagnosis or pre-diagnosis. It is preferably to use an antibody specific to a marker substance as a method for assaying the concn. of the marker substance. Also an assay can be conducted by capturing the marker substance on a carrier. The diabetes diagnosis or pre-diagnosis kit contg. an antibody specific to each marker substance enables to more conveniently perform diabetes diagnosis or pre-diagnosis. [on SciFinder(R)]},

keywords = {},

pubstate = {published},

tppubtype = {patent}

}